# EML4-ALK Fusion as a Resistance Mechanism to Osimertinib and Its Successful Management With Osimertinib and Alectinib: Case Report and Review of the Literature

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/eml4-alk-fusion-as-a-resistance-mechanism-to-osimertinib-and-its-successful/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Ullas Batra,Mansi Sharma,B. P. Amrith,Anurag Mehta,Praveen Jain |
| Citations | 25 |
| DOI | 10.1016/j.cllc.2020.05.016 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W3027340072 |
| PMID | 32620470 |
| Type | article |
| Year | 2020 |

## Paper authors

- [Mansi Sharma](https://scholariq.org/researchers/mansi-sharma/)

## Paper journal

- [Clinical Lung Cancer](https://scholariq.org/journals/clinical-lung-cancer/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer therapeutics and mechanisms](https://scholariq.org/topics/cancer-therapeutics-and-mechanisms/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.